Oct 7 (Reuters) – Maat Pharma SA: * MAAT PHARMA ANNOUNCES POSITIVE SECOND SAFETY INTERIM ANALYSIS FROM DSMB FOR PHASE 2B PHOEBUS TRIAL EVALUATING MAAT033 FOR PATIENTS RECEIVING ALLO-HSCT * MAAT PHARMA SA – MAAT033 SHOWS FAVORABLE SAFETY PROFILE AND TOLERABILITY
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
Oct 7 (Reuters) - Major stock markets in the Gulf were mixed in early trade…
By Maggie Fick and Soren Jeppesen LONDON/COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk has laid off dozens…
FRENCH FARM MINISTRY CUTS 2025 WINE PRODUCTION FORECAST TO 36.0 MLN HL FROM 37.4 MLN…
US S&P 500 E-MINI FUTURES DOWN 0.12%, DOW FUTURES DOWN 0.24%, NASDAQ 100 FUTURES DOWN…
By Sudip Kar-Gupta BRUSSELS (Reuters) -Dutch cryptocurrency company Amdax, which plans to launch a bitcoin…
(Updates with more information throughout from paragraphs 2-6) By Yantoultra Ngui SINGAPORE, Oct 7 (Reuters)…